Intermittent fasting for weight and fat loss: what the trials measured

Reviewed 15 sourcesPublished by PepVault

How much weight and fat intermittent fasting lost in the trials (16:8, 5:2, 4:3, alternate-day), set in one table beside the semaglutide and tirzepatide trials.

Blonde woman in an emerald crop top and white shorts dances while stirring a pot in a plant-filled kitchen
Last reviewed
Sources
15
Questions
6
Compounds
2

The short answer

In randomized trials, intermittent fasting (a daily eating window, 5:2, 4:3 or alternate-day fasting) lost about 3% of body weight in 8 weeks and about 5 to 8% over a year, close to what daily calorie cutting loses. About three-quarters of the loss was fat. The GLP-1 trials went further: semaglutide lost 14.9% at 68 weeks, tirzepatide up to 20.9% at 72.

  • The best year-long fasting result is 7.6% of body weight, from a 4:3 plan with intensive coaching.
  • In the drug trials the placebo groups also dieted and exercised, and lost 2.4 to 5.7%; the drug groups lost 14.9 to 20.9%.
  • Fasting and the drugs both lose roughly three parts fat to one part lean tissue; what differs is how much.
  • No trial has put fasting and a GLP-1 head to head.

Every number checked at its primary source · · 15 sources · How we research

Evidence: Randomized trials of intermittent fasting (8 weeks to 12 months), a 2026 Cochrane review of 22 trials and a 2025 network meta-analysis of 99; the GLP-1 numbers are from the phase 3 STEP 1, STEP 3 and SURMOUNT-1 trials and the Wegovy label. No trial has compared fasting with a GLP-1 directly.

Blonde woman in an emerald crop top and white shorts dances while stirring a pot in a plant-filled kitchen

How much weight does intermittent fasting lose?

Between 3% and 8% of body weight, depending on the plan and how long it ran. Intermittent fasting means you change when you eat: all food inside a daily window (time-restricted eating, such as 16:8), or very little on set days of the week (5:2, 4:3, alternate-day fasting). These are the randomized trials (pepvault.app/glossary/randomized-controlled-trial) that measured it in adults with overweight or obesity.

TrialPlanWho and how longWeight lost
Cienfuegos 2020Eating only 3 to 7 p.m. or 1 to 7 p.m., no calorie counting58 adults with obesity, 8 weeks−3.2% from the start in both window groups; controls +0.1%1
Jamshed 2022Eating 7 a.m. to 3 p.m., plus a calorie cut90 adults with obesity, 14 weeks−6.3 kg from the start; −4.0 kg with the same cut over 12 or more hours2
Harvie 20115:2, about 650 kcal (2,710 kJ) on 2 days a week107 premenopausal women, 6 months−6.4 kg from the start; −5.6 kg on a daily cut3
Trepanowski 2017Alternate-day: 25% of energy needs on fast days, 125% on the others100 adults with obesity, 12 months−6.8% at 6 months, −6.0% at 12, both against controls4
Lin 2023Eating noon to 8 p.m., no calorie counting90 adults with obesity, 12 months−4.87% against controls5
Liu 2022Eating 8 a.m. to 4 p.m., plus a calorie cap139 adults with obesity, 12 months−8.0 kg from the start; −6.3 kg on the calorie cap alone6
Catenacci 20254:3: 80% less energy on 3 days a week, plus coaching165 adults with overweight or obesity, 12 months−7.6% from the start; −5.0% on a matched daily cut715

The 4:3 trial is the strongest result so far. Both of its groups had group coaching and were asked to build up to 300 minutes of moderate activity a week; 58% of the 4:3 group lost 5% or more of their weight, against 47% on the daily cut715. Whether fasting beats plain calorie cutting across the other trials has its own guide (pepvault.app/guides/intermittent-fasting-on-a-glp-1): in most of them, it did not.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's Body page logs each weigh-in on a trend line toward your goal weight, and tracks body fat and waist with their change since your first entry, from a tape check-in or a smart scale's readings.

Download on the App Store

7 days free on the yearly plan for new subscribers.

How does intermittent fasting compare with semaglutide and tirzepatide?

The drug trials lost two to three times as much. They also ran longer, and every group in them, the placebo groups included, was on a diet-and-exercise plan. In STEP 1 and SURMOUNT-1 that plan aimed for 500 kcal a day less food and at least 150 minutes of activity a week910. In STEP 3 everyone started on 1,000 to 1,200 kcal a day for 8 weeks, then 1,200 to 1,800, with activity built up to 200 minutes a week10.

TrialTreatmentLengthWeight lostShare who lost 5%, 10% or 20% or more
Catenacci 20254:3 fasting with coaching12 months−7.6%75% or more: 58%15
STEP 1Placebo, with diet and activity advice68 weeks−2.4%810% or more: 12%10
STEP 3Placebo, with an intensive diet program68 weeks−5.7%1010% or more: 27.1%10
SURMOUNT-1Placebo, with diet and activity advice72 weeks−3.1%9Lost 20% or more: 3%9
STEP 1Semaglutide 2.4 mg weekly68 weeks−14.9%, or −15.3 kg810% or more: 66.1%10
STEP 3Semaglutide 2.4 mg weekly, intensive program68 weeks−16%1010% or more: 73%10
SURMOUNT-1Tirzepatide 5, 10 or 15 mg weekly72 weeks−15.0%, −19.5%, −20.9%9Lost 20% or more: 50% on 10 mg, 57% on 15 mg9

Read the placebo rows as the dieting groups they were. A strict diet with intensive support lost 5.7% at 68 weeks in STEP 3, inside the fasting trials' range10. The doses in the table are the trials' doses, given as that.

These trials enrolled different people and were never run against each other, so the table sets their numbers side by side; it is not a head-to-head result. As of November 2026 no trial has compared a fasting plan with a GLP-1 drug.

How much of the weight lost on intermittent fasting is fat?

Most of it, and about the same share as on a GLP-1. Body scans (DXA, a low-dose X-ray that splits the body into fat, lean tissue and bone) show the split. Lean mass (pepvault.app/glossary/lean-mass) is everything that is not fat or bone: muscle, organs and water.

TrialFat lostLean tissue lostFat as a share of the loss
Cienfuegos 2020, 4-hour window, 8 weeks−2.8 kg−0.8 kgAbout 78%1
Cienfuegos 2020, 6-hour window, 8 weeks−1.4 kg−1.5 kgAbout 48%1
Jamshed 2022, early window, 14 weeks−4.7 kg of −6.3 kg lostNot given in the summaryAbout 75%2
Harvie 2011, 5:2, 6 months (body-fat scale)Not given hereNot given here79%3
SURMOUNT-1 scan group, tirzepatide, 72 weeks−33.9% of fat mass−10.9% of lean mass74%11
SURMOUNT-1 scan group, placebo, 72 weeks−8.2% of fat mass−2.6% of lean mass75%11

Outside the 6-hour window group, the pattern holds across very different treatments: roughly three parts fat to one part lean tissue. In SURMOUNT-1's scan group of 160 people, tirzepatide and placebo lost the same three-to-one split, and the drug group lost 21.3% of body weight against 5.3%11. So the difference between fasting and a GLP-1 is mostly in how much weight goes, not in what kind. How to hold on to muscle while the weight comes off has its own guide (pepvault.app/guides/muscle-on-a-glp-1).

Commonly reported: the first few pounds on a fasting plan go fast, then the scale slows within a few weeks, and strength can dip on fast days or late in a long window.

PepVault's Body page logs each weigh-in on a trend line toward your goal weight, and tracks body fat and waist with their change since your first entry, from a tape check-in or a smart scale's readings. Track your weight in PepVault

Why does fasting lose less than a GLP-1?

Fasting works by eating less, and how much less is up to you every day. In the 4- and 6-hour window trial, people ate about 550 kcal a day less without counting1. In the early-window trial, eating from 7 a.m. to 3 p.m. did as much as cutting another 214 kcal a day2.

The gap shows when people have to hold the plan themselves. In the alternate-day trial, the fasting group ate more than prescribed on fast days and less on the days in between, and 38% dropped out, against 29% on the daily cut4. The 4:3 trial asked both groups for the same weekly deficit, about 34%; measured with doubly labeled water, the 4:3 group came closer to it, and 19% dropped out against 30% on the daily cut715.

A GLP-1 drug turns down hunger itself. The Wegovy label puts it plainly: GLP-1 is a natural regulator of appetite and calorie intake, its receptor sits in the brain areas that control appetite, and the drug also slows how fast the stomach empties10. Tirzepatide (pepvault.app/peptides/tirzepatide) adds a second gut hormone, GIP (pepvault.app/glossary/gip). The weekly shot keeps working on hunger whether or not the day's meals were planned around it.

What do the big reviews say about intermittent fasting for weight loss?

That fasting works about as well as standard diet advice, and better than doing nothing. The 2026 Cochrane review pooled 22 trials and 1,995 adults with overweight or obesity, followed for six to twelve months. Against regular diet advice, fasting differed by 0.33 percentage points of body weight, which the authors call little to no difference. Against no diet or a waiting list, it lost 3.42 percentage points more, which the authors still rate as little to no difference12.

A 2025 network meta-analysis (pepvault.app/glossary/meta-analysis) in the BMJ pooled 99 trials and 6,582 adults. Every fasting plan beat eating freely. Alternate-day fasting beat daily calorie cutting by 1.29 kg, mostly in short trials; in trials of 24 weeks or longer, no plan beat another13. Neither review reports a fasting result near the GLP-1 trials' 15 to 21% (the trial pages: pepvault.app/research/semaglutide-step-1-2021 and pepvault.app/research/tirzepatide-surmount-1-2022).

If you try intermittent fasting, how do you check it is working?

Measure it the way the trials did, so your number can be read against theirs.

  1. Pick one plan from the trials and keep its hours or days fixed, such as eating from noon to 8 p.m.5, or 5:2 at about 650 kcal on 2 days a week3.
  2. Weigh yourself first thing in the morning, before food, on the same scale each time.
  3. Measure your waist at the start and once a month after, at the same spot each time.
  4. At 8 weeks, work out your percent change (kilograms or pounds lost, divided by your starting weight, times 100): about 3% was the typical result at that point1.
  5. At 12 months, 5 to 8% is in line with the year-long trials457; in the 4:3 trial, 58% reached 5% or more15.
  6. Keep protein at each meal and strength training in the week, since about a quarter of the weight lost in these trials was lean tissue211.

PepVault's Food page sets one daily protein target from your profile and goal, and counts each meal you log against it. Track your food in PepVault

When to get help If you take insulin or a sulfonylurea for diabetes, talk to your prescriber before starting fast days: in the 5:2 trial in type 2 diabetes, those medicines were cut back at the start, and the medicine plan was tightened after cases of low blood sugar14.

Track it in the app

Sources

  1. Cienfuegos S, Gabel K, Kalam F, et al. Effects of 4- and 6-h time-restricted feeding on weight and cardiometabolic health: a randomized controlled trial in adults with obesity. Cell Metab. 2020;32(3):366-378.e3. PubMed 32673591
  2. Jamshed H, Steger FL, Bryan DR, et al. Effectiveness of early time-restricted eating for weight loss, fat loss, and cardiometabolic health in adults with obesity: a randomized clinical trial. JAMA Intern Med. 2022;182(9):953-962. PubMed 35939311
  3. Harvie MN, Pegington M, Mattson MP, et al. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond). 2011;35(5):714-727. PubMed 20921964
  4. Trepanowski JF, Kroeger CM, Barnosky A, et al. Effect of alternate-day fasting on weight loss, weight maintenance, and cardioprotection among metabolically healthy obese adults: a randomized clinical trial. JAMA Intern Med. 2017;177(7):930-938. PubMed 28459931
  5. Lin S, Cienfuegos S, Ezpeleta M, et al. Time-restricted eating without calorie counting for weight loss in a racially diverse population: a randomized controlled trial. Ann Intern Med. 2023;176(7):885-895. PubMed 37364268
  6. Liu D, Huang Y, Huang C, et al. Calorie restriction with or without time-restricted eating in weight loss. N Engl J Med. 2022;386(16):1495-1504. PubMed 35443107
  7. Catenacci VA, Ostendorf DM, Pan Z, et al. The effect of 4:3 intermittent fasting on weight loss at 12 months: a randomized clinical trial. Ann Intern Med. 2025;178(5):634-644. PubMed 40163873
  8. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
  9. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
  10. Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information (DailyMed, version 19, effective June 18, 2026): sections 12.1 and 14, Table 8 (its Studies 2 and 4 are STEP 1 and STEP 3). dailymed.nlm.nih.gov
  11. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. PubMed 39996356
  12. Garegnani LI, Oltra G, Ivaldi D, et al. Intermittent fasting for adults with overweight or obesity. Cochrane Database Syst Rev. 2026;2(2):CD015610. PubMed 41692034
  13. Semnani-Azad Z, Khan TA, Chiavaroli L, et al. Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials. BMJ. 2025;389:e082007. PubMed 40533200
  14. Carter S, Clifton PM, Keogh JB. Effect of intermittent compared with continuous energy restricted diet on glycemic control in patients with type 2 diabetes: a randomized noninferiority trial. JAMA Netw Open. 2018;1(3):e180756. PubMed 30646030
  15. University of Colorado Anschutz Medical Campus. Intermittent fasting outperforms calorie counting in weight loss study (news release on Catenacci 2025, with the investigators' figures), 2025. news.cuanschutz.edu

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo